Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, what the UK manufacturing capacity is of the covid-19 vaccine.

The Government has invested over £300 million to secure and scale up the UK’s manufacturing capabilities to be able to respond to the pandemic. This includes:

a) Facilities that have come online:

• £4.7 million for skills training through the Advanced Therapies Skills Training Network, which will be delivered through both virtual and physical centres;
• £8.75 million for the set-up of the rapid deployment facility at Oxford Biomedica in Oxfordshire; and
• £65.5 million for the early manufacture of the University of Oxford / AstraZeneca vaccine.
• We have also funded fill and finish through a contract with Wockhardt in Wrexham, North Wales which is currently providing Fill-Finish capabilities to the University of Oxford / AstraZeneca vaccine.

b) Facilities that will come online later this year, to help provide longer term UK capacity:

• £93 million to accelerate the completion and expanded role of the Vaccine Manufacturing Innovation Centre in Oxfordshire; and
• £127 million for the Cell and Gene Therapy Catapult Braintree in Essex.

In addition to the above, we have also funded the expansion of the Valneva factory in Livingston, Scotland.